Biopharmaceutical Contract Manufacturing Market (Biopharma CDMO / Biopharma CMO / Biologics Manufacturing) by Type of Service(s) Offered (API, FDF), Type of Biologic Manufactured (Antibodies, Cell Therapies, Vaccines and Other Biologics), Type of Expression System Used (Mammalian, Microbial and Others), Scale of Operation (Preclinical / Clinical and Commercial), Company Size (Small, Mid-sized, and Large and Very Large), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America and MENA): Industry Trends and Global Forecasts, 2022 – 2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    September 2022

  • Pages
    799

  • View Count
    38887

Example Insights

Biopharmaceutical-Contract-Manufacturing-Market-Context-thumb Biopharmaceutical-Contract-Manufacturing-Market-rise-thumb Biopharmaceutical-Contract-Manufacturing-Market-scales-of-operation-thumb Biopharmaceutical-Contract-Manufacturing-Market-Manufacturing-Organizations-thumb Biopharmaceutical-Contract-Manufacturing-Market-Contract-Manufacturers-thumb
Biopharmaceutical-Contract-Manufacturing-Market-Collaborations-thumb Biopharmaceutical-Contract-Manufacturing-Market-Acquisitions-thumb Biopharmaceutical-Contract-Manufacturing-Market-Recent-Expansions-thumb Biopharmaceutical-Contract-Manufacturing-Market-Pharma-Initiatives-thumb Biopharmaceutical-Contract-Manufacturing-Market-Production-Capacity-thumb
Biopharmaceutical-Contract-Manufacturing-Market-Supply-Analysis-thumb Biopharmaceutical-Contract-Manufacturing-Market-Key-Parameters-thumb Biopharmaceutical-Contract-Manufacturing-Market-Manufacturing-Market-thumb Biopharmaceutical-Contract-Manufacturing-Market-Scale-of-Operation-thumb  

Overview

The development pipelines of big biopharma companies are extensive and it is difficult for such players to carry out manufacturing operations using in house capacities. As a result, such companies often opt to outsource certain aspects of their production processes, predominantly drug substance manufacturing and aseptic filling. Therefore, there is a high demand for contract services from the aforementioned companies

-- Senior Manager Strategic Marketing, a Germany-based Large sized CMO

Over the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs. Further, with the advent of novel technologies, biologics have made a significant impact in the pharmaceutical domain, delivering ground-breaking treatment for a myriad of disease indications, including immunological, oncological and rare disorders. In this context, it is worth highlighting those 14 biopharmaceutical products (including cell therapies, gene therapies, monoclonal antibodies and recombinant proteins) were approved in the US alone, in 2021. Further, promising results from ongoing clinical research initiatives have encouraged various government and private firms to make significant investments in this domain. For instance, in 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. However, biologics manufacturing is fraught with various challenges. Some of the key concerns of contemporary innovators include rate of attrition of pipeline drugs / therapies, prolonged development timelines, current facility limitations, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Therefore, therapy developers are actively exploring avenues that enable them to overcome the existing challenges. Amongst other alternatives, outsourcing has emerged as a lucrative option for biologic drug developers. 

Currently, a significant number of players engaged in the biopharmaceutical domain prefer to outsource various operations to contract service providers (such as biologics manufacturing). In fact, currently over 275 companies claim to be biopharma CDMO / biopharma CMO, in compliance with the regulatory standards. It is also worth highlighting that biopharmaceutical contract manufacturers are actively trying to consolidate their presence in this field by entering into strategic alliances in order to meet the indubitably rising demand for biologics. For this purpose, substantial expansions, and mergers and acquisitions have been reported in this market, as service providers strive to become one-stop-shops, to cater to the diverse needs of their clientele. With outsourcing being increasingly accepted as a viable and beneficial business model within this field, we anticipate the biopharmaceutical contract manufacturing market (biopharma CDMO / biopharma CMO) to grow at a commendable pace in the coming years.

Scope of the Report

The “Biopharmaceutical Contract Manufacturing Market (biopharma CDMO / biopharma CMO / biologics manufacturing) by Type of Service(s) Offered (API, FDF), Type of Biologic Manufactured (Antibodies, Cell Therapies, Vaccines and Other Biologics), Type of Expression System Used (Mammalian, Microbial and Others), Scale of Operation (Preclinical / Clinical and Commercial), Company Size (Small, Mid-sized, and Large and Very Large), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America and MENA): Industry Trends and Global Forecasts, 2022 – 2035” report features an extensive study of the current market landscape and the likely future potential associated with the biopharmaceutical contract manufacturing market, over the next decade. 

The study also includes a detailed analysis of key drivers and trends within this evolving market. Amongst other elements, the report features:

  • A detailed overview of the overall landscape of companies engaged in offering contract manufacturing services for biologics, including a detailed analysis based on several relevant parameters, such as year of establishment, company size (based on number of employees), location of headquarters, type of service(s) offered (API and FDF manufacturing), type of biologic manufactured (ADCs, antibodies, biosimilars, cell therapies, gene therapies, nucleic acids / oligonucleotides, plasmid DNA / viral vectors, proteins / peptides, vaccines and others), scale of operation (preclinical, clinical and commercial), type of expression system used (mammalian, microbial and others), type of bioreactor used (single use, stainless steel and others) and mode of operation of bioreactor (batch, fed batch and perfusion / continuous).
  • A detailed landscape of the biopharmaceutical manufacturing facilities established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), highlighting the manufacturing hubs for biologics.  
  • Elaborate profiles of key industry players based in North America, Europe and Asia-Pacific that offer contract manufacturing services for biologics. Each profile features a brief overview of the company, details related to its biologic-related service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
  • A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the associated opportunities for biopharmaceutical CMOs and CDMOs. 
  • A case study comparing the key characteristics of small and large molecule drugs, along with details on the various steps involved in their respective manufacturing processes. 
  • A detailed discussion on the benefits and challenges associated with in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource the production operations.
  • A qualitative analysis, highlighting various factors that need to be taken into consideration by biopharmaceutical developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A review of the various biopharmaceutical-focused manufacturing initiatives undertaken by top 10 big pharma players (shortlisted on the basis of 2021 revenues), highlighting trends across various parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of biologic manufactured. 
  • An analysis of the recent collaborations within the biopharmaceutical contract manufacturing industry, based on several relevant parameters, such as year of partnership, type of partnership, type of biologic manufactured, therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have taken place in this domain, during the period 2015-2022.
  • A detailed analysis of the various mergers and acquisitions that have taken place within this domain, during the period 2015-2022, based on several relevant parameters, such as year of agreement, type of deal, geographical location of companies, type of acquisition, type of biologic manufactured and key value drivers.
  • A detailed review of expansion initiatives undertaken by biopharmaceutical contract manufacturers, during the period 2016-2022, along with information on several relevant parameters, such as year of expansion, purpose of expansion, type of biologic manufactured and location of expanded facility.
  • An analysis of the recent developments within the biopharmaceutical contract manufacturing industry, highlighting information on the funding investments made during the period 2016-2022, along with information on the technology advancements related to biomanufacturing. 
  • An estimate of the overall, installed capacity for the manufacturing of biopharmaceuticals, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity, based on size of manufacturer (small, mid-sized and large and very large), scale of operation (preclinical, clinical and commercial), type of expression system used (mammalian, microbial and others) and geography (North America, Europe, Asia-Pacific and Rest of the World).
  • An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.
  • A company size-wise, detailed analysis of the total cost of ownership for biopharmaceuticals contract manufacturing organizations, during the period 2022-2042.
  • A case study on the virtual business model concept, along with its role in the overall biopharmaceutical industry. It also features a discussion on the advantages and risks / challenges associated with outsourcing operations from virtual service providers.    
  • A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall biopharmaceutical industry. 
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract manufacturing services to biopharmaceutical developers.

One of the key objectives of the report was to estimate the existing market size and estimate the future size of biopharmaceutical contract manufacturing market. We have provided informed estimates on the evolution of the market, over the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of service(s) offered (API, FDF), [B] type of biologic manufactured (antibodies, cell therapies, vaccines and other biologics), [C] type of expression system used (mammalian, microbial and others), [D] scale of operation (preclinical / clinical and commercial), [E] company size (small, mid-sized, and large and very large), and [F] key geographical regions (North America, Europe, Asia-Pacific, Latin America and MENA). 

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players engaged in offering contract manufacturing services for biopharmaceuticals?
  • What are the different partnerships and expansion initiatives undertaken by biopharmaceutical contract manufacturers in the recent past?
  • Which regions represent the current key contract manufacturing hubs for biopharmaceuticals?
  • What is the current, installed capacity for contract manufacturing of biopharmaceuticals?
  • What is the current, global demand for biologics? How is the demand for such candidates likely to evolve in the foreseen future?    
  • What percentage of the biopharmaceuticals manufacturing operations are presently outsourced?
  • What factors should be taken into consideration while deciding whether the manufacturing operations for biopharmaceuticals should be kept in-house or outsourced?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biopharmaceuticals
3.3. Expression Systems for Biopharmaceuticals
3.3.1. Insect Expression Systems
3.3.2. Mammalian Expression Systems
3.3.3. Microbial Expression Systems
3.3.3.1. Bacterial Expression Systems
3.3.3.2. Fungal Expression Systems
3.3.3.3. Yeast Expression Systems
3.3.4. Plant Expression Systems
3.3.5. Mammalian versus Microbial Expression Systems

3.4. Manufacturing Process of Biopharmaceuticals
3.4.1. Upstream Processing
3.4.2. Fermentation
3.4.3. Downstream Processing

3.5. Overview of Contract Manufacturing
3.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
3.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
3.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations
3.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
3.7. Key Considerations While Selecting a Contract Manufacturing Partner
3.8. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Service(s) Offered
4.2.5. Analysis by Type of Biologic Manufactured
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Type of Expression System Used
4.2.8. Analysis by Type of Bioreactor Used
4.2.9. Analysis by Mode of Operation of Bioreactor

5. REGIONAL CAPABILITY ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Methodology
5.3. Overall Landscape of Biopharmaceutical Contract Manufacturing Facilities
5.3.1. Analysis by Type of Service(s) Offered
5.3.2. Analysis by Scale of Operation
5.3.3. Analysis by Type of Expression System Used
5.4. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
5.5. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
5.6. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific and Rest of the World

6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA
6.1. Chapter Overview
6.2. Regulatory Scenario of Biopharmaceutical Contract Manufacturing in the US
6.3. Leading Biopharmaceutical CMOs in North America

6.3.1. AGC Biologics
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.2.1. Process Development
6.3.1.2.2. cGMP Manufacturing
6.3.1.2.3. Quality and Regulatory
6.3.1.2.4. Process Validation
6.3.1.3. Financial Information
6.3.1.4. Manufacturing Facilities
6.3.1.5. Recent Developments and Future Outlook

6.3.2. Catalent (Catalent Pharma Solutions)
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.2.1. Cell Line Development
6.3.2.2.2. Manufacturing (Biomanufacturing)
6.3.2.2.3. ADCs and Bioconjugates Manufacturing
6.3.2.2.4. Biosimilars Development and Manufacturing
6.3.2.2.5. Proprietary Delivery and Fill / Finish Solutions
6.3.2.2.6. Analytical Services
6.3.2.3. Clinical Supply Services
6.3.2.4. Financial Information
6.3.2.5. Manufacturing Facilities
6.3.2.6. Recent Developments and Future Outlook

6.3.3. Cytiva (GE Healthcare)
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.2.1. Biomanufacturing Services
6.3.3.2.2. Scientific Support
6.3.3.2.3. OptiRun Service Solutions
6.3.3.2.4. Instruments Qualification Services
6.3.3.3. Financial Information
6.3.3.4. Manufacturing Facilities
6.3.3.5. Recent Developments and Future Outlook

6.3.4. FUJIFILM Diosynth Biotechnologies
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.2.1. Strain Development
6.3.4.2.2. Process Development
6.3.4.2.3. GMP Contract Manufacturing
6.3.4.2.4. Analytical Solutions
6.3.4.3. Financial Information
6.3.4.4. Manufacturing Facilities
6.3.4.5. Recent Developments and Future Outlook

6.3.5. KBI Biopharma
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.2.1. Process Development
6.3.5.2.2. Analytical Development
6.3.5.2.3. GMP Manufacturing
6.3.5.2.4. Clinical Cell Therapy Support
6.3.5.3. Recent Developments and Future Outlook

6.3.6. Patheon (acquired by Thermo Fisher Scientific)
6.3.6.1 Company Overview
6.3.6.2. Service Portfolio
6.3.6.2.1. Biologics
6.3.6.2.1.1. Drug Substance
6.3.6.2.2. Analytical Services
6.3.6.2.3. Product Development
6.3.6.2.4. Commercial Product Supply
6.3.6.3. Financial Information
6.3.6.4. Manufacturing Facilities
6.3.6.5. Recent Developments and Future Outlook
6.3.7. Piramal Pharma Solutions
6.3.7.1 Company Overview
6.3.7.2. Service Portfolio
6.3.7.2.1. Antibody Drug Conjugation Services
6.3.7.2.2. Other Services
6.3.7.3. Financial Information
6.3.7.4. Manufacturing Facilities
6.3.7.5. Recent Developments and Future Outlook

7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE
7.1. Chapter Overview
7.2. Biopharmaceutical Contract Manufacturing in Europe: Regulatory Scenario
7.2.1. EMA’s cGMP Regulations

7.3. Leading Biopharmaceutical CMOs in Europe

7.3.1. Boehringer Ingelheim (BioXcellence)
7.3.1.1. Company Overview
7.3.1.2. Service Portfolio
7.3.1.2.1. Process Development
7.3.1.2.1.1. Expression Systems
7.3.1.2.1.2. Upstream Technology
7.3.1.2.1.3. Downstream Technology
7.3.1.2.1.4. Other Process Development Services
7.3.1.2.2. Quality Assurance
7.3.1.2.3. Fill / Finish
7.3.1.3. Financial Information
7.3.1.4. Manufacturing Facilities
7.3.1.5. Recent Developments and Future Outlook

7.3.2. Lonza
7.3.2.1. Company Overview
7.3.2.2. Service Portfolio
7.3.2.3. Manufacturing Services
7.3.2.4. Financial Information
7.3.2.5. Manufacturing Facilities
7.3.2.6. Recent Developments and Future Outlook
7.3.3. Novasep
7.3.3.1 Company Overview
7.3.3.2. Service Portfolio
7.3.3.2.1. Services for Viruses and Viral Vectors
7.3.3.2.2. Services for Monoclonal Antibodies
7.3.3.2.3. Services for ADCs
7.3.3.2.4. Quality, Regulatory and Other Services
7.3.3.3. Manufacturing Facilities
7.3.3.4. Recent Developments and Future Outlook

7.3.4. Olon
7.3.4.1. Company Overview
7.3.4.2. Service Portfolio
7.3.4.3. Manufacturing Facilities
7.3.4.4. Recent Developments and Future Outlook

7.3.5. Rentschler Biopharma
7.3.5.1. Company Overview
7.3.5.2. Service Portfolio
7.3.5.2.1. Bioprocess Development
7.3.5.2.2. Biomanufacturing Services
7.3.5.2.3. Other Services
7.3.5.3. Manufacturing Facilities
7.3.5.4. Recent Developments and Future Outlook

7.3.6. Sandoz
7.3.6.1. Company Overview
7.3.6.2. Service Portfolio
7.3.6.3. Financial Information
7.3.6.4. Recent Developments and Future Outlook

8. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA-PACIFIC AND THE REST OF THE WORLD
8.1. Chapter Overview
8.2. Biopharmaceutical Contract Manufacturing in China
8.2.1. Biopharmaceutical Contract Manufacturing in China: Regulatory Scenario
8.2.2. Challenges Faced while Outsourcing to China
8.3. Leading Biopharmaceutical CMOs in China

8.3.1. WuXi Biologics
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.2.1. Discovery Services
8.3.1.2.2. Development Services
8.3.1.2.3. Testing Services
8.3.1.2.4. Clinical Manufacturing Services
8.3.1.2.5. Fill / Finish Operations
8.3.1.3. Financial Information
8.3.1.4. Manufacturing Facilities
8.3.1.5. Recent Developments and Future Outlook

8.4. Biopharmaceutical Contract Manufacturing in India
8.4.1. Biopharmaceutical Contract Manufacturing in India: Regulatory Scenario
8.4.2. Challenges Faced while Outsourcing to India

8.5. Leading Biopharmaceutical CMOs in India
8.5.1. Kemwell Biopharma
8.5.1.1. Company Overview
8.5.1.2. Service Portfolio
8.5.1.2.1. Development Services for Biopharmaceuticals
8.5.1.2.2. Manufacturing Services for Biopharmaceuticals
8.5.1.3. Manufacturing Facilities
8.5.1.4. Recent Developments and Future Outlook
8.6. Biopharmaceutical Contract Manufacturing in Japan
8.6.1. Biopharmaceutical Contract Manufacturing in Japan: Regulatory Scenario

8.7. Leading Biopharmaceutical CMOs in Japan
8.7.1. Minaris Regenerative Medicine
8.7.1.1. Company Overview
8.7.1.2. Service Portfolio
8.7.1.2.1. Manufacturing Development
8.7.1.2.2. GMP Manufacturing
8.7.1.3. Manufacturing Facilities
8.7.1.4. Recent Developments and Future Outlook

8.7.2. Takara Bio
8.7.2.1. Company Overview
8.7.2.2. Service Portfolio
8.7.2.3. Financial Information
8.7.2.4. Manufacturing Facilities
8.7.2.5. Recent Developments and Future Outlook

8.8. Biopharmaceutical Contract Manufacturing in South Korea
8.8.1. Biopharmaceutical Contract Manufacturing in South Korea: Regulatory Scenario
8.9. Leading Biopharmaceutical CMOs in South Korea
8.9.1. Celltrion
8.9.1.1. Company Overview
8.9.1.2. Service Portfolio
8.9.1.3. Financial Information
8.9.1.4. Manufacturing Facilities
8.9.1.5. Recent Developments and Future Outlook

8.9.2. Samsung BioLogics
8.9.2.1. Company Overview
8.9.2.2. Service Portfolio
8.9.2.2.1. Process Development
8.9.2.2.2. Analytical Services
8.9.2.2.3. cGMP Manufacturing Services
8.9.2.2.4. Aseptic Fill / Finish
8.9.2.2.5. Quality Services
8.9.2.2.6. Other Services
8.9.2.3. Financial Information
8.9.2.4. Manufacturing Facilities
8.9.2.5. Recent Developments and Future Outlook

8.10. Biopharmaceutical Contract Manufacturing in Australia
8.10.1. Biopharmaceutical Contract Manufacturing in Australia: Regulatory Scenario
8.11. Leading Biopharmaceutical CMOs in Australia
8.11.1. Cell Therapies
8.11.1.1. Company Overview
8.11.1.2. Service Portfolio
8.11.1.3. Manufacturing Facilities
8.11.1.4. Recent Developments and Future Outlook

8.11.2. Luina Bio
8.11.2.1. Company Overview
8.11.2.2. Service Portfolio
8.11.2.2.1. Microbial Products
8.11.2.2.2. Vaccines
8.11.2.2.3. Support Services
8.11.2.2.4. Quality-related Services
8.11.2.3. Manufacturing Facilities
8.11.2.4. Recent Developments and Future Outlook

9. NICHE BIOPHARMACEUTICAL SECTORS
9.1. Chapter Overview
9.2. Bispecific Antibodies
9.2.1. Introduction
9.2.2. Pipeline Analysis
9.2.2.1. Bispecific Antibody Therapeutics: Clinical Pipeline
9.2.2.2. Bispecific Antibody Therapeutics: Early Stage Pipeline
9.2.2.3. Multivalent Drug Candidates
9.2.3. Analysis by Phase of Development
9.2.4. Analysis by Target Indication
9.2.5. Bispecific Antibody Therapeutics: List of Technology Providers
9.2.6. Key Manufacturing Considerations and Challenges
9.2.7. Contract Manufacturing Scenario
9.2.7.1. CMOs Offering Services for Bispecific Antibodies

9.3. Antibody Drug Conjugates (ADCs)
9.3.1. Components of ADCs
9.3.1.1. Antibody
9.3.1.2. Cytotoxin
9.3.1.3. Linker
9.3.2. Manufacturing Process
9.3.3. Pipeline Analysis
9.3.4. Analysis by Phase of Development
9.3.5. Analysis by Target Indication
9.3.6. Key Technology Players: Analysis by Number of ADC Therapeutics
9.3.7. Novel Drug Conjugates
9.3.8. Key Manufacturing Considerations and Challenges
9.3.9. Contract Manufacturing Scenario
9.3.9.1. CMOs Offering Services for ADCs

9.4. Cell Therapies
9.4.1. Introduction
9.4.2. Current Market Landscape
9.4.3. Cell Therapy Manufacturing
9.4.3.1. Cell Therapy Manufacturing Models
9.4.3.1.1. Centralized Manufacturing
9.4.3.1.2. Decentralized Manufacturing

9.4.4. Key Manufacturing Considerations and Challenges
9.4.5. Factors Influencing Cell Therapy Manufacturing
9.4.5.1. Characterization
9.4.5.2. Cost of Goods
9.4.5.3. Automation of Cell Therapy Manufacturing
9.4.6. Analysis by Types of Cells Manufactured
9.4.7. Stem Cell Therapies: Analysis by Phase of Development
9.4.8. T-Cell Therapies: Analysis by Phase of Development
9.4.9. Contract Manufacturing Scenario
9.4.9.1. CMOs Offering Services for Cell Therapy

9.5. Gene Therapies
9.5.1. Gene Therapies Market: Pipeline Analysis
9.5.1.1. Analysis by Stage of Development
9.5.1.2. Analysis by Phase of Development
9.5.1.3. Analysis by Type of Vector Used
9.5.1.3.1. Clinical Pipeline
9.5.1.3.2. Preclinical Pipeline
9.5.1.4. Analysis by Target Indication
9.5.1.4.1. Clinical and Commercial Pipeline
9.5.1.4.1. Preclinical Pipeline
9.5.1.5. Analysis by Location of Manufacturing Facility
9.5.1.6 Analysis by Type of Viral Vector Used
9.5.2. Contract Manufacturing Scenario
9.5.2.1. CMOs Offering Services for Viral Vectors

9.6. Plasmid DNA
9.6.1. Introduction
9.6.2. Analysis by Location of Manufacturing Facility
9.6.3. Contract Manufacturing Scenario
9.6.3.1. CMOs Offering Services for Plasmid DNA

10. CASE STUDY: OUTSOURCING OF BIOSIMILARS
10.1. Chapter Overview
10.2. Biosimilars: An Introduction
10.3. Biosimilars: Development Stages
10.4. Regulatory Requirements for Licensing of Biosimilars
10.5. Need for Outsourcing Biosimilar Development and Manufacturing
10.6. Impact of Biosimilars on the Global Contract Manufacturing Market
10.6.1. Biosimilars: Historical Trend of FDA Approval
10.7. Biosimilars Contract Manufacturing Service Providers
10.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations

11. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES DRUGS / THERAPIES
11.1. Chapter Overview
11.2. Small Molecule and Large Molecule Drugs / Therapies
11.2.1. Comparison of General Characteristics
11.2.2. Comparison of Key Specifications
11.2.3. Comparison of Manufacturing Process
11.2.4. Comparison of Key Manufacturing Challenges

12. CASE STUDY: IN-HOUSE MANUFACTURING
12.1. Chapter Overview
12.2. In-House Manufacturing
12.2.1. Benefits Associated with In-House Manufacturing
12.2.2. Risks Associated with In-House Manufacturing
12.3. Outsourcing Trends in the Biopharmaceutical Industry
12.3.1. Types of Outsourcing Partners

12.4. Manufacturing Approaches Used for Approved Biologics, 2016-2022
12.4.1. Approved Biologics: Analysis by Company Size and Type of Manufacturing Model Adopted
12.4.2. Approved Biologics: Analysis by Company Size and Type of Biologic Manufactured
12.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
13.1. Chapter Overview
13.2. Assumptions and Key Parameters
13.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
13.3.1. Scenario 1
13.3.2. Scenario 2
13.3.3. Scenario 3
13.3.4. Scenario 4
13.4. Conclusion

14. BIG PHARMA INITIATIVES
14.1. Chapter Overview
14.2. Biopharmaceutical Related Initiatives of Big Pharmaceutical Players
14.2.1. Analysis by Number of Initiatives
14.2.2. Analysis by Year of Initiative
14.2.3. Analysis by Purpose of Initiative
14.2.4. Analysis by Type of Initiative
14.2.4.1. Analysis by Type of Partnership
14.2.4.2. Analysis by Type of Expansion
14.2.5. Analysis by Scale of Operation
14.2.6. Analysis by Type of Biologic Manufactured
14.2.7. Analysis by Year of Initiative and Company
14.2.8. Analysis by Purpose of Initiative and Company
14.2.9. Analysis by Year and Type of Initiative
14.2.10. Analysis by Region of Expansion and Company
14.2.11. Analysis by Type of Biologic Manufactured and Company
14.3. Competitive Benchmarking of Big Pharma Players

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Biopharmaceutical Contract Manufacturing: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Type of Biologic Manufactured
15.3.5. Analysis by Year of Partnership and Type of Biologic Manufactured
15.3.6. Analysis by Type of Partnership and Type of Biologic Manufactured
15.3.7. Analysis by Type of Biologic Manufactured and Geography
15.3.8. Analysis by Therapeutic Area
15.3.9. Most Active Players: Analysis by Number of Partnerships
15.3.10. Analysis by Region
15.3.10.1. Intracontinental and Intercontinental Agreements
15.3.10.2. Local and International Agreements

16. MERGERS AND ACQUISITIONS
16.1. Chapter Overview
16.2. Merger and Acquisition Models
16.3. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
16.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
16.3.2. Analysis by Type of Acquisition
16.3.3. Analysis by Region
16.3.3.1. Mergers and Acquisitions: Continent-wise Distribution
16.3.3.2. Mergers and Acquisitions: Country-wise Distribution
16.3.3.3. Mergers and Acquisitions: Year-wise Trend in North America, Europe and Asia-Pacific
16.3.4 Most Active Acquirers: Analysis by Number of Acquisitions
16.3.5 Analysis by Key Value Drivers
16.3.6. Analysis by Year of Acquisition and Key Value Drivers
16.3.7. Analysis by Type of Biologic Manufactured
16.3.8. Analysis by Key Value Drivers and Type of Biologic Manufactured
16.4. Key Acquisitions: Deal Multiples
16.4.1. Year-wise Trend of Deal Multiple Amount

17. RECENT EXPANSIONS
17.1. Chapter Overview
17.2. Biopharmaceutical Contract Manufacturing: Recent Expansions
17.2.1. Analysis by Year of Expansion
17.2.2. Analysis by Purpose of Expansion
17.2.3. Analysis by Year and Purpose of Expansion
17.2.4. Analysis by Type of Biologic Manufactured
17.2.5. Analysis by Purpose of Expansion and Type of Biologic Manufactured
17.2.6. Analysis by Location of Expanded Facility
17.2.7. Most Active Players: Analysis by Number of Recent Expansions
17.2.8. Analysis by Purpose of Expansion and Location of Expanded Facility
17.2.9. Analysis by Amount Invested
17.2.10. Recent Expansions: 2016-2020 and 2016-2022 Scenario

18. RECENT DEVELOPMENTS
18.1. Chapter Overview
18.2. Types of Funding
18.3. Biopharmaceutical Contract Manufacturing: Funding and Investments
18.3.1. Cumulative Year-wise Distribution by Number of Instances
18.3.2. Cumulative Year-wise Distribution of Amount Invested
18.3.3. Analysis of Instances by Type of Funding
18.3.4. Analysis of Total Amount Invested by Type of Funding
18.3.5. Analysis by Year and Type of Funding
18.3.6. Regional Analysis of Total Amount Invested and Number of Funding Instances (Continent-wise)
18.3.7. Regional Analysis of Total Amount Invested and Number of Funding Instances (Country-wise)
18.3.8. Most Active Players: Analysis by Number of Funding Instances
18.3.9. Most Active Players: Analysis by Total Amount Raised
18.3.10. Most Active Investors: Analysis by Number of Funding Instances
18.4. Technological Advancements
18.4.1. Single Use Technology
18.4.2. Process Analytical Technology (PAT)
18.4.3. Continuous Processing
18.4.4. Quality by Design (QbD) in Bio-Processing
18.4.5. Modular / Podular Biopharma Facilities

19. CAPACITY ANALYSIS
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Biopharmaceutical Contract Manufacturers: Global Production Capacity
19.3.1. Analysis by Company Size
19.3.2. Analysis by Type of Expression System Used
19.3.3. Analysis by Scale of Operation
19.3.4. Analysis by Region
19.3.4.1. Analysis of Biopharmaceutical Contract Manufacturing Capacity in North America
19.3.4.2. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Europe
19.3.4.3. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
19.4. Concluding Remarks

20. DEMAND ANALYSIS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Global Demand for Biopharmaceuticals
20.3.1. Analysis by Therapeutic Area
20.4. Relationship Between Annual Demand and Capacity
20.5. Annual Demand for Emerging Novel Biologics
20.5.1. ADC Therapeutics: Overall Annual Demand
20.5.2. ADC Therapeutics: Demand and Supply Analysis
20.6. Global Demand for Cell Therapy Manufacturing

21. TOTAL COST OF OWNERSHIP FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS
21.1. Chapter Overview
21.2. Key Parameters
21.3. Assumptions and Methodology
21.4. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2022-2042
21.5. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX and OPEX, 2023-2042
21.5.1. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, 2023-2042
21.5.2. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, 2023-2042

22. MARKET FORECAST AND OPPORTUNITY ANALYSIS
22.1. Chapter Overview
22.2. Key Assumptions and Methodology

22.3. Global Biopharmaceutical Contract Manufacturing Market, 2022-2035
22.4. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Service(s) Offered
22.4.1. Biopharmaceutical Contract Manufacturing Market for APIs, 2022-2035
22.4.2. Biopharmaceutical Contract Manufacturing Market for FDFs, 2022-2035

22.5. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Biologic Manufactured
22.5.1. Biopharmaceutical Contract Manufacturing Market for Antibodies, 2022-2035
22.5.2. Biopharmaceutical Contract Manufacturing Market for Cell Therapies, 2022-2035
22.5.3. Biopharmaceutical Contract Manufacturing Market for Vaccines, 2022-2035
22.5.4. Biopharmaceutical Contract Manufacturing Market for Other Biologics, 2022-2035

22.6. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Expression System Used
22.6.1. Biopharmaceutical Contract Manufacturing Market for Mammalian Cell-based Operations, 2022-2035
22.6.2. Biopharmaceutical Contract Manufacturing Market for Microbial Cell-based Operations, 2022-2035
22.6.3. Biopharmaceutical Contract Manufacturing Market for Other Expression System-based Operations, 2022-2035
22.7. Biopharmaceutical Contract Manufacturing Market: Analysis by Scale of Operation
22.7.1. Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, 2022-2035
22.7.2. Biopharmaceutical Contract Manufacturing Market for Commercial Operations, 2022-2035
22.8. Biopharmaceutical Contract Manufacturing Market: Analysis by Company Size, 2022-2035
22.8.1. Biopharmaceutical Contract Manufacturing Market for Small Companies, 2022-2035
22.8.2. Biopharmaceutical Contract Manufacturing Market for Mid-sized Companies, 2022-2035
22.8.3. Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, 2022-2035

22.9. Biopharmaceutical Contract Manufacturing Market: Analysis by Geography
22.9.1. Biopharmaceutical Contract Manufacturing Market in North America, 2022-2035
22.9.1.1. Biopharmaceutical Contract Manufacturing Market in the US, 2022-2035
22.9.1.2. Biopharmaceutical Contract Manufacturing Market in Canada, 2022-2035

22.9.2. Biopharmaceutical Contract Manufacturing Market in Europe, 2022-2035
22.9.2.1. Biopharmaceutical Contract Manufacturing Market in Italy, 2022-2035
22.9.2.2. Biopharmaceutical Contract Manufacturing Market in Germany, 2022-2035
22.9.2.3. Biopharmaceutical Contract Manufacturing Market in France, 2022-2035
22.9.2.4. Biopharmaceutical Contract Manufacturing Market in Spain, 2022-2035
22.9.2.5. Biopharmaceutical Contract Manufacturing Market in the UK, 2022-2035
22.9.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2022-2035

22.9.3. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2022-2035
22.9.3.1. Biopharmaceutical Contract Manufacturing Market in China, 2022-2035
22.9.3.2. Biopharmaceutical Contract Manufacturing Market in India, 2022-2035
22.9.3.3. Biopharmaceutical Contract Manufacturing Market in South Korea, 2022-2035
22.9.3.4. Biopharmaceutical Contract Manufacturing Market in Japan, 2022-2035
22.9.3.5. Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2022-2035
22.9.4. Biopharmaceutical Contract Manufacturing Market in Latin America, 2022-2035
22.9.5. Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2022-2035

23. CASE STUDY: VIRTUAL PHARMACEUTICAL COMPANIES
23.1. Chapter Overview
23.2. Historical Evolution of the Virtual Business Model
23.3. Virtual Pharmaceutical Companies as a Subset of the Overall Biopharmaceutical Industry
23.4. Advantages Associated with Outsourcing Operations to Service Providers
23.5. Key Challenges Associated with Outsourcing Operations to Service Providers

24. SWOT ANALYSIS
24.1 Chapter Overview
24.2. Strengths
24.3. Weaknesses
24.4. Opportunities
24.5. Threats
24.6. Comparison of SWOT Factors
24.7. Conclusion

25. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET
25.1. Chapter Overview
25.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
25.3. Shift from One-time Contracts to Strategic Partnerships
25.4. Integration / Adoption of Innovative Technologies
25.4.1. Single use Bioreactors
25.4.2. Novel Bioprocess Techniques
25.4.3. Bioprocess Automation
25.5. Focus on Niche Therapeutic Areas
25.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
25.7. Capability and Expertise Expansions by CMOs to become One-Stop-Shops
25.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
25.9. Increase in Financial Inflow and Outsourcing Budgets
25.10. Challenges Faced by both Sponsors and Service Providers
25.10.1. Concerns Related to Single Use Systems
25.10.2. Issues Related to Capacity Fluctuations
25.11. Concluding Remarks

26. SURVEY ANALYSIS
26.1. Chapter Overview
26.1.1. Overview of Respondents
26.1.2. Analysis by Designation of Respondents
26.2. Analysis by Biologic Manufacturing Expertise
26.3. Analysis by Scale of Manufacturing
26.4. Analysis by Location of Production Facilities
26.5. Analysis by Type of Expression System Used
26.6. Analysis by Type of Bioreactor Used
26.7. Analysis by Mode of Operation of Bioreactor

27. CONCLUSION
27.1. Chapter Overview

28. INTERVIEW TRANSCRIPTS
28.1. Chapter Overview
28.2. Andrea Conforto, Sales & Marketing, Bioservices Director, Olon
28.3. Astrid Brammer, Key Account Manager, Richter Helm
28.4. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
28.5. Christian Bailly, ex-Director of CDMO, Pierre Fabre
28.6. Claire Otjes, Communication Manager, Batavia Biosciences
28.7. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
28.8. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
28.9. Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
28.10. Jeffrey Hung, General Manager, Vigene Biosciences
28.11. Kevin Daley, Director Pharmaceuticals, Novasep
28.12. Mark Wright, ex-Site Head, Grangemouth, Piramal Healthcare
28.13. Max Rossetto, General Manager – Business Development, Luina Bio
28.14. Nicolas Grandchamp, R&D Leader, GEG Tech
28.15. Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
28.16. Sebastian Schuck, Head of Business Development, Wacker Biotech
28.17. Tatjana Buchholz, Marketing Manager, Plasmid Factory and Marco Schmeer, ex-Project Manager
28.18. Tim Oldham, ex- Chief Executive Officer, Cell Therapies
28.19. Traci Kyes, Vice President of Commercial Operations, Arranta Bio
28.20. Vijayakumar Ramaraj, Chief Manager, Shilpa Biologicals

29. APPENDIX I: TABULATED DATA

30. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Mergers and Acquisitions
Figure 2.4 Executive Summary: Recent Expansions
Figure 2.5 Executive Summary: Demand Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Biopharmaceuticals
Figure 3.2 Types of Expression Systems Used for the Production of Biopharmaceuticals
Figure 3.3 Stages of the Biomanufacturing Process
Figure 3.4 Types of Third-Party Service Providers
Figure 3.5 Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations
Figure 4.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Figure 4.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Biopharmaceutical Contract Manufacturers: Distribution by Company Size, Year of Establishment and Location of Headquarters
Figure 4.6 Biopharmaceutical CMOs: Distribution by Type of Service(s) Offered
Figure 4.7 Biopharmaceutical CMOs: Distribution by Type of Biologic Manufactured
Figure 4.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters
Figure 4.9 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Company Size
Figure 4.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Figure 4.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Figure 4.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Figure 4.13 Biopharmaceutical Contract Manufacturers: Distribution by Types of Expression Systems Used and Location of Headquarters
Figure 4.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Figure 4.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Figure 5.1 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Figure 5.2 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service(s) Offered
Figure 5.3 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Figure 5.4 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Expression System Used
Figure 5.5 Regional Capability Analysis: Biopharmaceutical Contract Manufacturers in North America
Figure 5.6 Regional Capability Analysis: Biopharmaceutical Contract Manufacturers in Europe
Figure 5.7 Regional Capability Analysis: Biopharmaceutical Contract Manufacturers in Asia-Pacific and Rest of the World
Figure 6.1 Biopharmaceutical Industry: The US Market Scenario
Figure 6.2 Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges
Figure 6.3 US FDA Guidelines: Elements of a Quality Agreement
Figure 6.4 US FDA Guidelines: Key Considerations for Biologic Manufacturing Operations
Figure 6.5 AGC Biologics: Annual Revenues, FY 2017-Q1 2022 (JPY Billion)
Figure 6.6 Catalent: Service Portfolio
Figure 6.7 Catalent: Biosimilars Service Portfolio
Figure 6.8 Catalent: Annual Revenues, FY 2017-9M 2022 (USD Million)
Figure 6.9 Cytiva: Service Portfolio
Figure 6.10 Cytiva: Annual Revenues, FY 2017-FY 2021 (USD Million)
Figure 6.11 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 6.12 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2017-FY 2021 (JPY Billion)
Figure 6.13 FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
Figure 6.14 KBI Biopharma: Service Portfolio
Figure 6.15 Patheon: Service Portfolio
Figure 6.16 Patheon: Services and Solutions for Biologics
Figure 6.17 Patheon: Annual Revenues, FY 2017-FY 2021 (USD Million)
Figure 6.18 Piramal Enterprises: Annual Revenues, FY 2017-FY 2021 (INR Crores)
Figure 7.1 Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
Figure 7.2 EMA GMP Guidelines: Key Considerations of the Contract Giver, Contract Acceptor and the Contract
Figure 7.3 Boehringer Ingelheim: Service Portfolio
Figure 7.4 Boehringer Ingelheim: Annual Revenues, FY 2017-FY 2021 (EUR Billion)
Figure 7.5 Lonza: Service Portfolio
Figure 7.6 Lonza: Annual Revenues, FY 2017-FY 2021 (CHF Billion)
Figure 7.7 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Figure 7.8 Novasep: Product Portfolio
Figure 7.9 Rentschler Biopharma: Service Portfolio
Figure 7.10 Sandoz: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Figure 8.1 Chinese Regulatory Guidelines: Key Considerations of the Contract Giver
Figure 8.2 Chinese Regulatory Guidelines: Key Considerations of the Contract Acceptor
Figure 8.3 Chinese Regulatory Guidelines: Key Aspects of the Contract
Figure 8.4 Biopharmaceutical Contract Manufacturing in China: Challenges
Figure 8.5 WuXi Biologics: Service Portfolio
Figure 8.6 Wuxi Biologics: Annual Revenues, FY 2017-FY 2021 (RMB Million)
Figure 8.7 Biopharmaceutical Contract Manufacturing in India: Growth Drivers
Figure 8.8 Biopharmaceutical Contract Manufacturing in India: Challenges
Figure 8.9 Minaris Regenerative Medicine: Service Portfolio
Figure 8.10 Takara Bio: Service Portfolio
Figure 8.11 Takara Bio: Annual Revenues, FY 2017-FY 2021 (JPY Million)
Figure 8.12 Celltrion: Service Portfolio
Figure 8.13 Celltrion: Annual Revenues, FY 2017-Q1 2022 (KRW Billion)
Figure 8.14 Samsung BioLogics: Service Portfolio
Figure 8.15 Samsung BioLogics: Annual Revenues, FY 2017-Q1 2022 (KRW Billion)
Figure 8.16 Cell Therapies: Service Portfolio
Figure 8.17 Luina Bio: Service Portfolio
Figure 9.1 Structure of a Bispecific Antibody
Figure 9.2 Bispecific Antibody Therapeutics Pipeline: Distribution by Phase of Development
Figure 9.3 Bispecific Antibody Therapeutics Pipeline: Distribution by Target Indication
Figure 9.4 Structure of an Antibody Drug Conjugate (ADC)
Figure 9.5 Antibody Drug Conjugates: Distribution by Status of Development
Figure 9.6 Antibody Drug Conjugates: Distribution by Target Indication
Figure 9.7 Key ADC Technology Providers: Distribution by Number of Candidates
Figure 9.8 Decentralized Manufacturing: Process Model
Figure 9.9 Cell Therapy Manufacturing: Challenges and Growth Drivers
Figure 9.10 Cell Therapy: Potency as Critical Quality Attribute
Figure 9.11 Stem Cell Therapies: Distribution by Phase of Development
Figure 9.12 T-Cell Therapies: Distribution by Phase of Development
Figure 9.13 Gene Therapies: Distribution by Stage of Development
Figure 9.14 Gene Therapies: Distribution by Phase of Development
Figure 9.15 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Figure 9.16 Early-Stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Figure 9.17 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 9.18 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 9.19 Viral Vector Manufacturers: Distribution by Location of Manufacturing Facility
Figure 9.20 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Figure 10.1 Manufacturing Stages of a Biosimilar Product
Figure 10.2 Analytical and Functional Characterization Methods for Key Biosimilar Product
Figure 10.3 Regulatory Process Adopted for Licensing of a Biosimilar Product
Figure 10.4 Need for Outsourcing Biosimilar Manufacturing Operations
Figure 10.5 Biosimilars: Historical Trend of FDA Approval, 2015-2021
Figure 10.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations
Figure 11.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2021
Figure 11.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 12.1 Benefits Associated with In-House Manufacturing
Figure 12.2 Risks Associated with In-House Manufacturing
Figure 12.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships
Figure 13.1 Make versus Buy Decision Making Framework
Figure 13.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 14.1 Big Pharma Players: Distribution by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives, 1980-2022
Figure 14.2 Big Pharma Players: Cumulative Distribution by Year of Initiative
Figure 14.3 Big Pharma Players: Distribution by Purpose of Initiative
Figure 14.4 Big Pharma Players: Distribution by Type of Initiative
Figure 14.5 Big Pharma Players: Distribution by Type of Partnership
Figure 14.6 Big Pharma Players: Distribution by Type of Expansion
Figure 14.7 Big Pharma Players: Distribution by Scale of Operation
Figure 14.8 Big Pharma Players: Distribution by Type of Biologic Manufactured
Figure 14.9 Big Pharma Players: Distribution by Year of Initiative and Company (Heat Map Representation)
Figure 14.10 Big Pharma Players: Distribution by Purpose of Initiative and Company
Figure 14.11 Big Pharma Players: Distribution by Year and Type of Initiative
Figure 14.12 Big Pharma Players: Distribution by Region of Expansion and Company
Figure 14.13 Big Pharma Players: Distribution by Type of Biologic Manufactured and Company
Figure 14.14 Big Pharma Players: Distribution of Top Pharmaceutical Companies (Heat Map Representation)
Figure 15.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Figure 15.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Figure 15.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured
Figure 15.7 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured and Geography
Figure 15.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 15.9 Most Active Players: Distribution by Number of Partnerships
Figure 15.10 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 15.11 Partnerships and Collaborations: Local and International Agreements
Figure 16.1 Mergers and Acquisitions: Year-Wise Cumulative Trend (2015- 2022)
Figure 16.2 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 16.3 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Figure 16.4 Mergers and Acquisitions: Distribution by Region (Country-wise)
Figure 16.5 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific (2015- 2022)
Figure 16.6 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 16.7 Catalent Biologics: Information on Key Acquisitions
Figure 16.8 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 16.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 16.10 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Figure 16.11 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Figure 16.12 Mergers and Acquisitions: Year-Wise Trend of Deal Multiple Amount (USD Million)
Figure 17.1 Recent Expansions: Cumulative Year-wise Trend, 2016-2022
Figure 17.2 Recent Expansions: Distribution by Purpose of Expansion
Figure 17.3 Recent Expansions: Distribution by Year and Purpose of Expansion
Figure 17.4 Recent Expansions: Distribution by Type of Biologic Manufactured
Figure 17.5 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Figure 17.6 Recent Expansions: Distribution by Location of Expanded Facility
Figure 17.7 Most Active Players: Distribution by Number of Recent Expansions
Figure 17.8 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Figure 17.9 Recent Expansions: Distribution by Amount Invested (USD Million)
Figure 17.10 Recent Expansions: Regional Comparison 2016-2020 and 2016-2022 Scenario
Figure 18.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Number of Funding Instances, 2016-2022
Figure 18.2 Funding and Investments: Cumulative Year-wise Trend of Total Amount Invested, 2016-2022 (USD Million)
Figure 18.3 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding
Figure 18.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 18.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 18.6 Funding and Investment Analysis: Distribution of Number of Funding Instances and Total Amount Invested by Geography (Continent-wise) (USD Million)
Figure 18.7 Funding and Investment Analysis: Distribution of Number of Funding Instances and Total Amount Invested by Geography (Country-wise) (USD Million)
Figure 18.8 Most Active Players: Distribution by Number of Funding Instances
Figure 18.9 Most Active Players: Distribution by Total Amount Invested (USD Million)
Figure 18.10 Most Active Investors: Analysis by Number of Funding Instances
Figure 19.1 Capacity Analysis: Distribution by Company Size
Figure 19.2 Capacity Analysis: Distribution by Type of Expression System Used
Figure 19.3 Capacity Analysis: Distribution by Scale of Operation
Figure 19.4 Capacity Analysis: Distribution by Region
Figure 19.5 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in North America
Figure 19.6 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Europe
Figure 19.7 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Figure 20.1 Global Demand for Biopharmaceuticals, 2022-2035 (in kilograms)
Figure 20.2 Demand Analysis: Distribution of Annual Demand by Therapeutic Area
Figure 20.3 Demand and Supply Scenario for Biopharmaceuticals, 2022-2035 (Million Liters)
Figure 20.4 Demand Analysis: Annual Demand for ADC Therapeutics (in kilograms), 2022-2030
Figure 20.5 ADC Therapeutics: Demand and Supply Scenario, 2022-2030
Figure 20.6 Global Demand for Cell Therapies, 2022-2030 (in terms of Number of Patients)
Figure 20.7 Global Demand for Cell Therapies, 2022-2030 (Billion Cells)
Figure 21.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 21.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 21.3 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2022-2042 (USD Million)
Figure 21.4 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Distribution by CAPEX and OPEX, 2023 and 2042 (USD Million)
Figure 21.5 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2023: Distribution by CAPEX (USD Million)
Figure 21.6 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2023-2042: Distribution by OPEX (USD Million)
Figure 22.1 Global Biopharmaceutical Contract Manufacturing Market, 2022-2035 (USD Billion)
Figure 22.2 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service(s) Offered
Figure 22.3 Biopharmaceutical Contract Manufacturing Market for APIs, 2022-2035 (USD Billion)
Figure 22.4 Biopharmaceutical Contract Manufacturing Market for FDFs, 2022-2035 (USD Billion)
Figure 22.5 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured
Figure 22.6 Biopharmaceutical Contract Manufacturing Market for Antibodies, 2022-2035 (USD Billion)
Figure 22.7 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, 2022-2035 (USD Billion)
Figure 22.8 Biopharmaceutical Contract Manufacturing Market for Vaccines, 2022-2035 (USD Billion)
Figure 22.9 Biopharmaceutical Contract Manufacturing Market for Other Biologics, 2022-2035 (USD Billion)
Figure 22.10 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used
Figure 22.11 Biopharmaceutical Contract Manufacturing Market for Mammalian Cell-based Operations, 2022-2035 (USD Billion)
Figure 22.12 Biopharmaceutical Contract Manufacturing Market for Microbial Cell-based Operations, 2022-2035 (USD Billion)
Figure 22.13 Biopharmaceutical Contract Manufacturing Market for Other Expression System-based Operations, 2022-2035 (USD Billion)
Figure 22.14 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
Figure 22.15 Biopharmaceutical Contract Manufacturing Market for Clinical Operations, 2022-2035 (USD Billion)
Figure 22.16 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, 2022-2035 (USD Billion)
Figure 22.17 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size
Figure 22.18 Biopharmaceutical Contract Manufacturing Market for Small Companies, 2022-2035 (USD Billion)
Figure 22.19 Biopharmaceutical Contract Manufacturing Market for Mid-sized Companies, 2022-2035 (USD Billion)
Figure 22.20 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, 2022-2035 (USD Billion)
Figure 22.21 Biopharmaceutical Contract Manufacturing Market: Distribution by Geography
Figure 22.22 Biopharmaceutical Contract Manufacturing Market in North America, 2022-2035 (USD Billion)
Figure 22.23 Biopharmaceutical Contract Manufacturing Market in the US, 2022-2035 (USD Billion)
Figure 22.24 Biopharmaceutical Contract Manufacturing Market in Canada, 2022-2035 (USD Billion)
Figure 22.25 Biopharmaceutical Contract Manufacturing Market in Europe, 2022-2035 (USD Billion)
Figure 22.26 Biopharmaceutical Contract Manufacturing Market in Italy, 2022-2035 (USD Billion)
Figure 22.27 Biopharmaceutical Contract Manufacturing Market in Germany, 2022-2035 (USD Billion)
Figure 22.28 Biopharmaceutical Contract Manufacturing Market in France, 2022-2035 (USD Billion)
Figure 22.29 Biopharmaceutical Contract Manufacturing Market in Spain, 2022-2035 (USD Billion)
Figure 22.30 Biopharmaceutical Contract Manufacturing Market in the UK, 2022-2035 (USD Billion)
Figure 22.31 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2022-2035 (USD Billion)
Figure 22.32 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2022-2035 (USD Billion)
Figure 22.33 Biopharmaceutical Contract Manufacturing Market in China, 2022-2035 (USD Billion)
Figure 22.34 Biopharmaceutical Contract Manufacturing Market in India, 2022-2035 (USD Billion)
Figure 22.35 Biopharmaceutical Contract Manufacturing Market in South Korea, 2022-2035 (USD Billion)
Figure 22.36 Biopharmaceutical Contract Manufacturing Market in Japan, 2022-2035 (USD Billion)
Figure 22.37 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2022-2035 (USD Billion)
Figure 22.38 Biopharmaceutical Contract Manufacturing Market in Latin America, 2022-2035 (USD Billion)
Figure 22.39 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2022-2035 (USD Billion)
Figure 23.1 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market (USD Billion)
Figure 23.2 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Contract Manufacturing Market in 2022 (USD Billion)
Figure 24.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis
Figure 24.2 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2005-2022
Figure 24.3 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 26.1 Survey Analysis: Distribution of Respondents by Company Type
Figure 26.2 Survey Analysis: Distribution of Respondents by Location of Headquarters
Figure 26.3 Survey Analysis: Distribution of Respondents by Designation
Figure 26.4 Survey Analysis: Distribution by Biologics Manufacturing Expertise
Figure 26.5 Survey Analysis: Distribution by Scale of Manufacturing
Figure 26.6 Survey Analysis: Distribution by Location of Production Facilities
Figure 26.7 Survey Analysis: Distribution by Type of Expression System Used
Figure 26.8 Survey Analysis: Distribution by Type of Bioreactor Used
Figure 26.9 Survey Analysis: Distribution by Mode of Operation of Bioreactor
Figure 27.1 Concluding Remarks: Overall Market Landscape
Figure 27.2 Concluding Remarks: Partnerships and Collaborations
Figure 27.3 Concluding Remarks: Mergers and Acquisitions
Figure 27.4 Concluding Remarks: Recent Expansions
Figure 27.5 Concluding Remarks: Capacity Analysis
Figure 27.6 Concluding Remarks: Demand Analysis
Figure 27.7 Concluding Remarks: Market Forecast and Opportunity Analysis
Figure 27.8 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 3.1 Mammalian versus Microbial Expression Systems
Table 4.1 List of Biopharmaceutical Contract Manufacturers
Table 4.2 Biopharmaceutical Contract Manufacturers: Information on Type of Service(s) Offered
Table 4.3 Biopharmaceutical Contract Manufacturers: Information on Type of Biologic Manufactured
Table 4.4 Biopharmaceutical CMOs: Information on Scale of Operation
Table 4.5 Biopharmaceutical Contract Manufacturers: Information on Type of Expression Systaem Used
Table 4.6 Biopharmaceutical Contract Manufacturers: Information on Type of Bioreactor Used
Table 4.7 Biopharmaceutical Contract Manufacturers: Information on Mode of Operation of Bioreactor
Table 5.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
Table 5.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
Table 5.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific and Rest of the World
Table 6.1 AGC Biologics: Company Overview
Table 6.2 AGC Biologics: Biologics Manufacturing Facilities
Table 6.3 AGC Biologics: Recent Developments and Future Outlook
Table 6.4 Catalent: Company Overview
Table 6.5 Catalent: Biologics Manufacturing Facilities
Table 6.6 Catalent: Recent Developments and Future Outlook
Table 6.7 Cytiva: Company Overview
Table 6.8 Cytiva: Manufacturing Facilities
Table 6.9 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 6.10 FUJIFILM Diosynth Biotechnologies: Biopharmaceutical Facilities
Table 6.11 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 6.12 KBI Biopharma: Company Overview,
Table 6.13 KBI Biopharma: Overview of Manufacturing Capabilities
Table 6.14 KBI Biopharma: Recent Developments and Future Outlook
Table 6.15 Patheon: Company Overview
Table 6.16 Patheon: Biopharmaceutical Manufacturing and Development Facilities
Table 6.17 Patheon: Future Outlook
Table 6.18 Piramal Pharma Solutions: Company Overview
Table 6.19 Piramal Pharma Solutions: Facilities
Table 6.20 Piramal Pharma Solutions: Recent Developments and Future Outlook
Table 7.1 FDA Quality Agreement and EMA cGMP Regulations: A Comparative Analysis
Table 7.2 Boehringer Ingelheim: Company Overview
Table 7.3 Boehringer Ingelheim: Biopharmaceutical Facilities
Table 7.4 Boehringer Ingelheim: Recent Developments and Future Outlook
Table 7.5 Lonza: Company Overview
Table 7.6 Lonza: Biopharmaceutical Facilities
Table 7.7 Lonza: Recent Developments and Future Outlook
Table 7.8 Novasep: Company Overview
Table 7.9 Novasep: Biologics Manufacturing Facilities
Table 7.10 Novasep: Recent Developments and Future Outlook
Table 7.11 Olon: Company Overview
Table 7.12 Olon: Biopharmaceutical Facilities
Table 7.13 Olon: Recent Developments and Future Outlook
Table 7.14 Rentschler Biopharma: Company Overview
Table 7.15 Rentschler Biopharma: Recent Developments and Future Outlook
Table 7.16 Sandoz: Company Overview
Table 8.1 WuXi Biologics: Company Overview
Table 8.2 WuXi Biologics: Recent Developments and Future Outlook
Table 8.3 Kemwell Biopharma: Company Overview
Table 8.4 Kemwell Biopharma: Recent Developments and Future Outlook
Table 8.5 Minaris Regenerative Medicine: Company Overview
Table 8.6 Minaris Regenerative Medicine: Manufacturing Facilities
Table 8.7 Minaris Regenerative Medicine: Recent Developments and Future Outlook
Table 8.8 Takara Bio: Company Overview
Table 8.9 Takara Bio: Biologics Manufacturing Facilities
Table 8.10 Takara Bio: Recent Developments and Future Outlook
Table 8.11 Celltrion: Company Overview
Table 8.12 Celltrion: Biologics Manufacturing Facilities
Table 8.13 Celltrion: Recent Developments and Future Outlook
Table 8.14 Samsung BioLogics: Company Overview
Table 8.15 Samsung BioLogics: Biopharmaceutical Facilities
Table 8.16 Samsung BioLogics: Recent Developments and Future Outlook
Table 8.17 Cell Therapies: Company Overview
Table 8.18 Cell Therapies: Recent Developments and Future Outlook
Table 8.19 Luina Bio: Company Overview
Table 8.20 Luina Bio: Recent Developments and Future Outlook
Table 9.1 Bispecific Antibody Therapeutics: Information on Developer(s), Platform / Technology Used, Phase of Development, Target Antigens and Antibody Format
Table 9.2 Bispecific Antibody Therapeutics: Information on Developer(s), Technology Used, Phase of Development, Target Antigens, Mechanism of Action, Disease Indication, Therapeutic Area and Broader Disease Segment
Table 9.3 List of Other Emerging Multivalent Drug Candidates
Table 9.4 Bispecific Antibody Therapeutics: List of Technology Platforms
Table 9.5 Bispecific Antibody Contract Manufacturers: List of Companies
Table 9.6 Commonly Used Cytotoxins for ADC Therapeutics
Table 9.7 Occupational Exposure Limit Bands, Safebridge Consultants
Table 9.8 Antibody Drug Conjugates: Drug Pipeline
Table 9.9 Novel Drug Conjugates: List of Developers
Table 9.10 ADC Contract Manufacturers: List of Companies
Table 9.11 Applications of Cell-based Therapies
Table 9.12 Cell-based Therapies: Commercialized Products,
Table 9.13 Assessments for Key Cell Therapy Manufacturing Steps
Table 9.14 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 9.15 Cell Therapy Manufacturing (Industry Players): Information on Type of Cell Manufactured
Table 9.16 Cell Therapy Contract Manufacturers: List of Cell Therapy Contract Manufacturers
Table 9.17 Cell Therapy Contract Manufacturers: List of Non-Industry Players
Table 9.18 Viral Vectors Manufacturers: Information on Type of Viral Vector Used
Table 9.19 Viral Vectors Contract Manufacturers: List of Companies,
Table 9.20 Plasmid DNA Contract Manufacturers: List of Companies
Table 10.1 List of Biosimilars Contract Manufacturing Service Providers
Table 11.1 Small Molecules and Large Molecules: Strengths and Weaknesses
Table 11.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
Table 11.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 12.1 List of FDA Approved Biologics (2016-2022)
Table 14.1 Big Pharma Players: List of Biopharmaceutical Manufacturing Initiatives
Table 15.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations, 2015-2022
Table 15.2 Partnerships and Collaborations: Information on Type of Biologic Manufactured
Table 16.1 Biopharmaceutical Contract Manufacturing: List of Mergers and Acquisitions, 2015-2022
Table 16.2 Biopharmaceutical Contract Manufacturing Mergers and Acquisitions: Information on Key Value Drivers and Type of Biologic Manufactured, 2015- 2022
Table 16.3 Mergers and Acquisitions: Information on Deal Multiples, 2015-2022
Table 17.1 Biopharmaceutical Contract Manufacturing: List of Recent Expansions
Table 18.1 Biopharmaceutical Contract Manufacturing Market: Funding and Investment
Table 18.2 Funding and Investment Analysis: Summary of Investments
Table 18.3 Funding and Investment Analysis: Summary of Venture Capital Funding
Table 19.1 Capacity Analysis: Information on Contract Biomanufacturing Capacity
Table 19.2 Capacity Analysis: Average Capacity per Category (Sample Data Set)
Table 19.3 Capacity Analysis: Average Capacity for Mammalian Expression System (Sample Data Set)
Table 19.4 Capacity Analysis: Average Capacity for Microbial Expression System (Sample Data Set)
Table 19.5 Capacity Analysis: Global Contract Biomanufacturing Capacity
Table 20.1 Annual Biomanufacturing Capacity, 2022-2035 (Million Liters)
Table 20.2 ADC Therapeutics: Annual Demand for Outsourcing, 2022-2030 (in kilograms)
Table 20.3 ADC Therapeutics: Annual Supply for Outsourcing, 2022-2030 (in kilograms)
Table 23.1 List of Virtual Biopharmaceutical Companies
Table 24.1 Global Biopharmaceuticals Market: Patent Approval and Expiry Details of Best-selling Biologics
Table 26.1 Survey Analysis: Overview of Respondents
Table 26.2 Survey Analysis: Distribution of Respondents by Designation
Table 26.3 Survey Analysis: Biologics Manufacturing Expertise
Table 26.4 Survey Analysis: Scale of Manufacturing
Table 26.5 Survey Analysis: Location of Production Facilities
Table 26.6 Survey Analysis: Type of Expression System Used
Table 26.7 Survey Analysis: Type of Bioreactor Used
Table 26.8 Survey Analysis: Mode of Operation of Bioreactor
Table 29.1 Biopharmaceutical CMOs: Distribution by Year of Establishment
Table 29.2 Biopharmaceutical CMOs: Distribution by Company Size
Table 29.3 Biopharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Table 29.4 Biopharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
Table 29.5 Biopharmaceutical CMOs: Distribution by Company Size, Year of Establishment and Location of Headquarters
Table 29.6 Biopharmaceutical CMOs: Distribution by Type of Service(s) Offered
Table 29.7 Biopharmaceutical CMOs: Distribution by Type of Biologic Manufactured
Table 29.8 Biopharmaceutical CMOs: Distribution by Type of Biologic Manufactured and Location of Headquarters
Table 29.9 Biopharmaceutical CMOs: Distribution by Type of Biologic Manufactured and Company Size
Table 29.10 Biopharmaceutical CMOs: Distribution by Scale of Operation
Table 29.11 Biopharmaceutical CMOs: Distribution by Type of Biologic Manufactured and Scale of Operation
Table 29.12 Biopharmaceutical CMOs: Distribution by Type of Expression System Used
Table 29.13 Biopharmaceutical CMOs: Distribution by Type of Expression System Used and Location of Headquarters
Table 29.14 Biopharmaceutical CMOs: Distribution by Type of Bioreactor Used
Table 29.15 Biopharmaceutical CMOs: Distribution by Mode of Operation of Bioreactor
Table 29.16 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Table 29.17 Biopharmaceutical Contract Manufacturing Facilities: Distribution of Type of Service(s) Offered
Table 29.18 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Table 29.19 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Expression System Used
Table 29.20 AGC Biologics: Annual Revenues FY 2017-Q1 2022 (JPY Billion)
Table 29.21 Catalent: Annual Revenues, FY 2017-9M 2022 (USD Million)
Table 29.22 Cytiva: Annual Revenues, FY 2017-FY 2021 (USD Million)
Table 29.23 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2017-FY 2021 (JPY Billion)
Table 29.24 FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
Table 29.25 Patheon: Annual Revenues, FY 2017-FY 2021 (USD Million)
Table 29.26 Piramal Enterprises: Annual Revenues, FY 2017-FY 2021 (INR Crores)
Table 29.27 Boehringer Ingelheim: Annual Revenues, FY 2017-FY 2021 (EUR Billion)
Table 29.28 Lonza: Annual Revenues, FY 2017-FY 2021 (CHF Billion)
Table 29.29 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Table 29.30 Sandoz: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Table 29.31 WuXi Biologics: Annual Revenues, FY 2017-FY 2021 (RMB Million)
Table 29.32 Takara Bio: Annual Revenues, FY 2017-FY 2021 (JPY Million)
Table 29.33 Celltrion: Annual Revenues, FY 2017-Q1 2022 (KRW Billion)
Table 29.34 Samsung Biologics: Annual Revenues, FY 2017-Q1 2022 (KRW Billion)
Table 29.35 Bispecific Antibody Therapeutics Pipeline: Distribution by Phase of Development
Table 29.36 Bispecific Antibody Therapeutics Pipeline: Distribution by Target Indication
Table 29.37 Antibody Drug Conjugates: Distribution by Status of Development
Table 29.38 Antibody Drug Conjugates: Distribution by Target Indication
Table 29.39 Key ADC Technology Providers: Distribution by Number of Candidates
Table 29.40 Stem Cell Therapies: Distribution by Phase of Development
Table 29.41 T-Cell Therapies: Distribution by Phase of Development
Table 29.42 Gene Therapies: Distribution by Stage of Development
Table 29.43 Gene Therapies: Distribution by Phase of Development
Table 29.44 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 29.45 Early-Stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 29.46 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 29.47 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 29.48 Viral Vector Manufacturers: Distribution by Location of Manufacturing Facility
Table 29.49 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 29.50 Biosimilars: Historical Trend of FDA Approval, 2015-2021
Table 29.51 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2021
Table 29.52 Big Pharma Players: Distribution by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives, 1980-2022
Table 29.53 Big Pharma Players: Cumulative Distribution by Year of Initiative
Table 29.54 Big Pharma Players: Distribution by Purpose of Initiative
Table 29.55 Big Pharma Players: Distribution by Type of Initiative
Table 29.56 Big Pharma Players: Distribution by Type of Expansion
Table 29.57 Big Pharma Players: Distribution by Scale of Operation
Table 29.58 Big Pharma Players: Distribution by Type of Biologic Manufactured
Table 29.59 Big Pharma Players: Distribution by Purpose of Initiative and Company
Table 29.60 Big Pharma Players: Distribution by Year and Type of Initiative
Table 29.61 Big Pharma Players: Distribution by Region of Expansion and Company
Table 29.62 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Table 29.63 Partnerships and Collaborations: Distribution by Type of Partnership
Table 29.64 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Table 29.65 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Table 29.66 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured and Geography
Table 29.67 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 29.68 Most Active Players: Distribution by Number of Partnerships
Table 29.69 Partnerships and Collaborations: Local and International Agreements
Table 29.70 Mergers and Acquisitions: Cumulative Year-Wise Trend (2015-2022)
Table 29.71 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 29.72 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Table 29.73 Mergers and Acquisitions: Distribution by Region (Country-wise)
Table 29.74 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific (2015-2022)
Table 29.75 Most Active Acquirers: Distribution by Number of Acquisitions
Table 29.76 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 29.77 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 29.78 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Table 29.79 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Table 29.80 Mergers and Acquisitions: Year-wise Trend of Deal Multiple Amount (USD Million)
Table 29.81 Recent Expansions: Cumulative Year-wise Trend, 2016-2022
Table 29.82 Recent Expansions: Distribution by Purpose of Expansion
Table 29.83 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 29.84 Recent Expansions: Distribution by Type of Biologic Manufactured
Table 29.85 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Table 29.86 Recent Expansions: Distribution by Location of Expanded Facility
Table 29.87 Most Active Players: Distribution by Number of Recent Expansions
Table 29.88 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Table 29.89 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 29.90 Funding and Investment Analysis: Cumulative Year-wise Trend of Number of Funding Instances, 2016-2022
Table 29.91 Funding and Investment Analysis: Cumulative Year-wise Trend of Total Amount Invested, 2016-2022 (USD Million)
Table 29.92 Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding
Table 29.93 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 29.94 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2016-2022
Table 29.95 Funding and Investment Analysis: Distribution of Number of Funding Instances and Total Amount Invested by Geography (Continent-wise) (USD Million)
Table 29.96 Funding and Investment Analysis: Distribution of Number of Funding Instances and Total Amount Invested by Geography (Country-wise) (USD Million)
Table 29.97 Most Active Players: Distribution by Number of Funding Instances
Table 29.98 Most Active Players: Distribution by Total Amount Raised (USD Million)
Table 29.99 Most Active Investors: Distribution by Number of Funding Instances
Table 29.100 Capacity Analysis: Distribution by Company Size
Table 29.101 Capacity Analysis: Distribution by Type of Expression System Used
Table 29.102 Capacity Analysis: Distribution by Scale of Operation
Table 29.103 Capacity Analysis: Distribution by Region
Table 29.104 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in North America
Table 29.105 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Europe
Table 29.106 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Table 29.107 Global Demand for Biopharmaceuticals, 2022-2035 (in kilograms)
Table 29.108 Demand Analysis: Distribution of Annual Demand by Therapeutic Area
Table 29.109 Demand and Supply Scenario for Biopharmaceuticals, 2022-2035 (Million Liters)
Table 29.110 Demand Analysis: Annual Demand for ADC Therapeutics (in kilograms), 2022-2030
Table 29.111 Global Demand for Cell Therapies, 2022-2030 (in terms of Number of Patients)
Table 29.112 Global Demand for Cell Therapies, 2022-2030 (Billion Cells)
Table 29.113 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2022-2042 (USD Million)
Table 29.114 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Distribution by CAPEX and OPEX, 2023 and 2042 (USD Million)
Table 29.115 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2023: Distribution of CAPEX (USD Million)
Table 29.116 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, 2023-2042: Distribution by OPEX (USD Million)
Table 29.117 Global Biopharmaceutical Contract Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.118 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service(s) Offered, 2022 and 2035
Table 29.119 Biopharmaceutical Contract Manufacturing Market for APIs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.120 Biopharmaceutical Contract Manufacturing Market for FDFs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.121 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured
Table 29.122 Biopharmaceutical Contract Manufacturing Market for Antibodies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.123 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.124 Biopharmaceutical Contract Manufacturing Market for Vaccines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.125 Biopharmaceutical Contract Manufacturing Market for Other Biologics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.126 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used
Table 29.127 Biopharmaceutical Contract Manufacturing Market for Mammalian Cell-based Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.128 Biopharmaceutical Contract Manufacturing Market for Microbial Cell-based Operations, Conservative, Base and Optimistic Scenarios 2022-2035 (USD Billion)
Table 29.129 Biopharmaceutical Contract Manufacturing Market for Other Expression System-based Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.130 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
Table 29.131 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.132 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.133 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size
Table 29.134 Biopharmaceutical Contract Manufacturing Market for Small Companies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.135 Biopharmaceutical Contract Manufacturing Market for Mid-sized Companies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.136 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.137 Biopharmaceutical Contract Manufacturing Market: Distribution by Geography
Table 29.138 Biopharmaceutical Contract Manufacturing Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.139 Biopharmaceutical Contract Manufacturing Market in the US, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.140 Biopharmaceutical Contract Manufacturing Market in Canada, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.141 Biopharmaceutical Contract Manufacturing Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.142 Biopharmaceutical Contract Manufacturing Market in Italy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.143 Biopharmaceutical Contract Manufacturing Market in Germany, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.144 Biopharmaceutical Contract Manufacturing Market in France, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.145 Biopharmaceutical Contract Manufacturing Market in Spain, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.146 Biopharmaceutical Contract Manufacturing Market in the UK, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.147 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.148 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.149 Biopharmaceutical Contract Manufacturing Market in China, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.150 Biopharmaceutical Contract Manufacturing Market in India, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.151 Biopharmaceutical Contract Manufacturing Market in South Korea, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.152 Biopharmaceutical Contract Manufacturing Market in Japan, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.153 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.154 Biopharmaceutical Contract Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.155 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 29.156 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market in 2022 (USD Billion)
Table 29.157 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2005-2022
Table 29.158 Survey Analysis: Distribution of Respondents by Company Type
Table 29.159 Survey Analysis: Distribution of Respondents by Location of Headquarters
Table 29.160 Survey Analysis: Distribution of Respondents by Designation
Table 29.161 Survey Analysis: Distribution by Biologics Manufacturing Expertise
Table 29.162 Survey Analysis: Distribution by Scale of Manufacturing
Table 29.163 Survey Analysis: Distribution by Location of Production Facilities
Table 29.164 Survey Analysis: Distribution by Type of Expression System Used
Table 29.168 Survey Analysis: Distribution by Mode of Operation of Bioreactor

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3P Biopharmaceuticals
  2. 3SBio
  3. 4TEEN4 Pharmaceuticals
  4. 53Biologics
  5. AR BROWN
  6. Aalto Scientific
  7. AavantiBio
  8. AB2 Bio
  9. AbbVie
  10. AbbVie Contract Manufacturing
  11. AbCellera
  12. AbClon
  13. Abeona Therapeutics
  14. ABL
  15. ABL Bio
  16. Abogen Biosciences
  17. Abzena
  18. AC Immune
  19. Acasti Pharma
  20. Accellta
  21. Accinov
  22. ACES Pharma
  23. Achilles Therapeutics
  24. Acticor Biotech
  25. Adagene
  26. AdAlta
  27. Adaptimmune Therapeutics
  28. AdaptVac
  29. Adare Pharmaceuticals
  30. ADC Biotechnology (Acquired by Sterling Pharma Solutions)
  31. Adimmune
  32. ADM Biopolis
  33. Advanced Biotherapeutics Consulting
  34. Advanced Cell Technology and Engineering
  35. Advanced Scientifics (Acquired by Thermo Fisher Scientific)
  36. Advaxis
  37. Advent Bioservices
  38. Aeras
  39. Affibody
  40. Affinita Biotech
  41. Affinity Life Sciences
  42. Affymetrix
  43. Afton Scientific
  44. AGC Biologics
  45. Agilis Biotherapeutics
  46. Agilux Laboratories
  47. Airway Therapeutics
  48. Ajinomoto Althea
  49. Ajinomoto Bio-Pharma Services
  50. Akorn
  51. Akouos
  52. Akron Biotech
  53. Akshaya Bio
  54. Alcami
  55. Aldevron
  56. Alexion
  57. Alira Health
  58. AllCells
  59. Allele Biotechnology & Pharmaceuticals
  60. Allergan
  61. Allergy Therapeutics
  62. Allevi
  63. Alliance Protein Laboratories (Acquired by KBI Biopharma)
  64. Alligator Bioscience
  65. Almac
  66. Almirall
  67. Alphamab
  68. Alteogen
  69. Altimmune
  70. Altor BioScience
  71. Amaran Biotechnology
  72. Amatsigroup (Acquired by Eurofins)
  73. AmbioPharm
  74. American Peptide Company (Acquired by Bachem)
  75. Amgen
  76. Ampersand Capital Partners
  77. AM-Pharma
  78. AMRI
  79. Andes Biotechnologies
  80. ANL Bio
  81. Antabio
  82. Anthos Therapeutics
  83. apceth Biopharma
  84. Aptevo Therapeutics
  85. Aravive Biologics
  86. Arcellx
  87. Arch Biopartners
  88. ArchiMed
  89. Arcturus Therapeutics
  90. Arcus Biosciences
  91. Arecor
  92. argenx
  93. Arranta Bio
  94. Aruvant Sciences
  95. Asahi Kasei
  96. ASC Therapeutics
  97. Ash Stevens
  98. Asher Biotherapeutics
  99. ASLAN Pharmaceuticals
  100. Aspire Health Science
  101. Asterias Biotherapeutics
  102. Astero Bio
  103. Astorg
  104. AstraZeneca
  105. Asymchem
  106. Asymptote (Acquired by GE Healthcare)
  107. Atara Biotherapeutics
  108. Athersys
  109. aTyr Pharma
  110. Aumgene Biosciences
  111. Aurinia Pharmaceuticals
  112. Austrianova
  113. AutekBio
  114. Autolus Therapeutics
  115. Avecia (Acquired by Nitto Denko)
  116. AveXis
  117. Avid Bioservices
  118. Avrio Biopharmaceuticals
  119. Axcellerate Pharma
  120. Axovant Gene Therapies
  121. Babraham Bioscience Technologies
  122. Baccinex
  123. Bachem
  124. BacThera
  125. Batavia Biosciences
  126. Battelle
  127. Baxter
  128. Baxter BioPharma Solutions
  129. Bayer
  130. Baylor College of Medicine
  131. Baylor Institute for Immunology Research
  132. Baylor Scott & White Research Institute (BSWRI)
  133. BCN Peptides
  134. Beam Therapeutics
  135. BeiGene
  136. Beijing Kawin Technology
  137. Berkeley Lights
  138. BeRNA Therapeutics
  139. Bexion Pharmaceuticals
  140. Bharat Biotech
  141. BIA Separations (Acquired by Sartorius)
  142. BIBITEC
  143. BiBo Pharma
  144. BINEX
  145. Bio Elpida
  146. Bio Farma
  147. Bioasis Technologies
  148. BioCell
  149. BioCentriq
  150. BioCina
  151. BioConnection
  152. Biodextris
  153. Bio-Ess Laboratories
  154. Biofabri
  155. Biogen
  156. BioInno Bioscience
  157. Bioinova
  158. BioInvent
  159. Biological E.
  160. BioMARC
  161. Biomay
  162. BioMeca
  163. Biomedical Advanced Research and Development Authority (BARDA)
  164. Biomeva (Acquired by AGC)
  165. Biomunex
  166. BiondVax Pharmaceuticals
  167. Bionova Scientific
  168. BioNTech
  169. BioNTech IMFS
  170. Bioqube Ventures
  171. BiosanaPharma
  172. BioSciencesCorp
  173. biose
  174. BioSig Technologies
  175. Bio-Synthesis
  176. BioTechnique
  177. Biotecnol
  178. BioVaxys Technology
  179. BioVectra
  180. Bioverativ
  181. Biovian
  182. Bioworkshops
  183. BioXcellence
  184. BioXpress Therapeutics
  185. BJ Bioscience
  186. BJP Laboratories
  187. Bliss Biopharmaceutical
  188. Bloom Science
  189. Blue Stream Laboratories
  190. bluebird bio
  191. Bluejay Therapeutics
  192. Boehringer Ingelheim
  193. Boston Children’s Hospital
  194. Boston Institute of Biotechnology
  195. BPL Biologics
  196. BrainStorm Cell Therapeutics
  197. Brammer Bio
  198. Brenus Pharma
  199. BriaCell Therapeutics
  200. Bright Peak Therapeutics
  201. Bristol Myers Squibb
  202. Bryllan
  203. BSP Pharmaceuticals
  204. Burrard Pharmaceuticals
  205. Buzzard Pharmaceuticals
  206. C3i Center
  207. Caisson Biotech
  208. Caladrius Biosciences
  209. Calviri
  210. Calypso Biotech
  211. CANbridge
  212. CANbridge Pharmaceuticals
  213. Cancer Research Technology
  214. Canton Biologics
  215. Capricor Therapeutics
  216. Capsugel
  217. Captozyme
  218. CARBOGEN AMCIS
  219. CaroGen
  220. Catalent Biologics
  221. Catalyst Biosciences
  222. Catapult Therapy TCR (Acquired by Cell Medica)
  223. CDR-Life
  224. Cedar Pharmaceuticals
  225. Cell and Gene Therapy Catapult
  226. Cell Culture Company
  227. Cell Medica
  228. Cell Therapies
  229. Celladon
  230. Cell-Easy
  231. Cellectis
  232. CELLforCURE
  233. CellGenix
  234. Cellin Technologies
  235. CELLINK
  236. Cellipont Bioservices
  237. Cellpoint Bioservices (Formerly known as Performance Cell Manufacturing)
  238. Celltrion
  239. Cellular Biomedicine Group
  240. Cellular Therapeutics
  241. CellVec
  242. Celonic
  243. Celsion
  244. Celsis (Acquired by Charles River Laboratories)
  245. Cenexi
  246. Centaur Biopharmaceutical Services
  247. Center for Breakthrough Medicines
  248. Center for Innovation in Advanced Development and Manufacturing
  249. Centers for Disease Control and Prevention
  250. Coalition for Epidemic Preparedness Innovations (CEPI)
  251. Cerbios-Pharma
  252. Cerium Pharmaceuticals
  253. CEVEC Pharmaceuticals
  254. Charles River Laboratories
  255. Chemomab Therapeutics
  256. ChemPartner
  257. Chime Biologics
  258. Chimeron Bio
  259. China Regenerative Medicine International
  260. Chinese Peptide Company
  261. Chiome Bioscience
  262. CHO Pharma
  263. Chord Therapeutics (Acquired by Merck)
  264. CiMaas
  265. Cipla
  266. CiRA Foundation
  267. Citryll
  268. Clean Biologics
  269. Clean Cells
  270. CMAB Biopharma
  271. CMC Biologics
  272. CMIC
  273. Coalition for Epidemic Preparedness Innovations
  274. Cobra Biologics
  275. Cognate BioServices
  276. Coherus BioSciences
  277. Coldstream Laboratories
  278. Columbia University
  279. CombiGene
  280. Contract Manufacturing & Development
  281. Cook MyoSite
  282. CordenPharma
  283. Coretherapix
  284. Covance
  285. CPC Scientific
  286. CPI
  287. CR Pharmaceutical
  288. CRC for Cell Therapy Manufacturing
  289. Creative Biolabs
  290. Crescendo Biologics
  291. CRISPR Therapeutics
  292. Cryoport
  293. CSBio
  294. CSL
  295. CureCell
  296. CureVac
  297. Curia
  298. Cytiva
  299. CytoDyn
  300. Cytosen Therapeutics
  301. Cytovance Biologics
  302. CyTuVax
  303. Daiichi Sankyo
  304. Dalton Pharma Services
  305. Danaher
  306. DanDrit Biotech
  307. DaTaMabs
  308. Decibel Therapeutics
  309. Delphi Genetics
  310. Denali Therapeutics
  311. Dendreon
  312. DeoBioSciences
  313. Department of Defense
  314. DiNAQOR
  315. Disposable-Lab (Acquired by Eurofins)
  316. DM Bio
  317. Drugs for Neglected Diseases?initiative (DNDi)
  318. Dyadic International
  319. Dyax
  320. Eden Biologics
  321. Educell
  322. EirGenix
  323. Eisai
  324. Elion Labs
  325. Emendo Biotherapeutics
  326. Emergent BioSolutions
  327. Emerson
  328. Encure Biopharma
  329. Enimmune
  330. Enleofen Bio
  331. Enterobiome
  332. Enzene Biosciences
  333. Enzolytics
  334. ERC Belgium
  335. Erytech Pharma
  336. Esco Aster
  337. Etinpro
  338. EuBiologics
  339. Eucodis Bioscience
  340. EUFETS
  341. Eurocine Vaccines
  342. Eurofins Scientific
  343. Eurogentec
  344. Euticals
  345. EVER Pharma
  346. evitria
  347. Evologic Technologies
  348. Excellos
  349. ExCellThera
  350. Exelead
  351. Exelisis
  352. Exelixis
  353. Exothera
  354. FairJourney Biologics
  355. Fapon Biopharma
  356. Faron Pharmaceuticals
  357. FinVector
  358. FloDesign Sonics
  359. Florida Biologix
  360. FluGen
  361. Forecyte Bio
  362. Formycon
  363. For?Robin
  364. Forty Seven (Acquired by Gilead Sciences)
  365. Forum for Innovative Regenerative Medicine
  366. Fred Hutchinson Cancer Research Center
  367. Freeline Therapeutics
  368. FUJIFILM Diosynth Biotechnologies
  369. Fusion Antibodies
  370. Fzata
  371. Gadea Pharmaceutical (Acquired by AMRI)
  372. Gallant Custom Laboratories
  373. Gamida Cell
  374. GC Cell
  375. GC Pharma
  376. GE Healthcare
  377. Gedeon Richter
  378. GeneCure Biotechnologies
  379. GeneDesign
  380. Genentech
  381. GeneOne Life Science
  382. Geneos Therapeutics
  383. GeneQuantum Healthcare
  384. GeneScience Pharmaceuticals
  385. Genethon
  386. Genexine
  387. Genezen
  388. GenIbet
  389. GenIbet Biopharmaceuticals
  390. Genmab
  391. Genome & Company
  392. Genopis
  393. Genovior Biotech
  394. Genprex
  395. GenScript
  396. GenScript ProBio
  397. GigaGen
  398. Gilead Sciences
  399. Ginkgo Bioworks
  400. Gladstone
  401. GlycoSeLect
  402. Glycotope
  403. Goodwin Biotechnology
  404. Government of Canada
  405. Government of UK
  406. GP Pharm
  407. Grand River Aseptic Manufacturing
  408. Great Point Partners
  409. Green Cross LabCell
  410. GreenLight Biosciences
  411. GreenPak Biotech
  412. Greffex
  413. Grenoble Hospital
  414. Griffith University
  415. GSK
  416. GT Biopharma
  417. GTP Bioways
  418. GTP Technology
  419. Gubra
  420. H.I.G. Capital
  421. HaemaLogiX
  422. HALIX
  423. Hangzhou Redox BIO
  424. Hansa Biopharma
  425. Harbin Hou pu Tong tang Biotechnology
  426. Harbour BioMed
  427. Harpoon Therapeutics
  428. Harpoon Therapeutics
  429. HDT Bio
  430. Heidelberg Pharma
  431. Helixmith
  432. Hemogenyx
  433. Hepalink USA
  434. Hepatic Cell Therapy Support
  435. Hile Bio-Technology
  436. Histocell
  437. Hitachi Chemical
  438. Hong Kong Institute of Biotechnology
  439. Hookipa Biotech
  440. Horizon Discovery
  441. Horizon Pharma
  442. Horizon Therapeutics
  443. Hospira
  444. Houston Methodist Research Institute
  445. Humanigen
  446. Hummingbird Bioscience
  447. Hybio Pharmaceutical
  448. Hycult Biotech
  449. HYGEIA Group
  450. IAVI
  451. IBC Generium
  452. Icagen
  453. Ichnos Sciences
  454. ID Pharma
  455. IDT Biologika
  456. I-Mab Biopharma
  457. Immatics
  458. Immune Pharmaceuticals
  459. Immunitas Therapeutics
  460. ImmunoCellular Therapeutics
  461. Immunocore
  462. ImmunoGenesis
  463. Immunome
  464. Immunomedics
  465. ImmunoTek Bio Centers
  466. Immutep (Formerly known as Prima BioMed)
  467. Imperial College London
  468. Imperial Innovations
  469. In3Bio
  470. IncoCell Tianjin
  471. Indapta Therapeutics
  472. Indian Immunologicals
  473. IndyGeneUS AI
  474. Inhibrx
  475. InnoBation Bio
  476. Innovation Network Corporation of Japan
  477. Innovative Biotech
  478. Innovative NeuroTechnologies
  479. InnovaVector
  480. Inovio Pharmaceuticals
  481. Inpac Probiotics
  482. INSERM-ANRS
  483. Institute for Research
  484. Integrated DNA Technologies
  485. Integrity Bio
  486. IntellectiveBio
  487. International AIDS Vaccine Initiative
  488. International Consortium
  489. International Stem Cell Corporation
  490. Intervacc
  491. Intravacc
  492. Invenra
  493. Invetech
  494. Iovance Biotherapeutics
  495. iProgen Biotech
  496. IQVIA
  497. FUJIFILM Irvine Scientific
  498. IsoPlexis
  499. Istituto Biochimico Italiano Giovanni Lorenzini
  500. Iveric Bio
  501. JAFRAL
  502. Janssen Pharmaceuticals
  503. Japan Tissue Engineering
  504. Japanese Society for Regenerative Medicine
  505. Jeneil Biotech
  506. JHL Biotech
  507. Jitsubo
  508. Jo Lab
  509. Johns Hopkins University
  510. Johnson & Johnson
  511. JOINN Biologics
  512. JOINN Laboratories
  513. JSR
  514. Jubilant HollisterStier
  515. Juniper Pharmaceuticals
  516. Juno Pharmaceuticals
  517. Juno Therapeutics
  518. Just-Evotec Biologics
  519. JW CreaGene
  520. JW Therapeutics
  521. KABS Pharmaceutical Services
  522. KAHR Medical
  523. Kamat Pharmatech
  524. Kanaph Therapeutics
  525. Kanda BioTech
  526. Kaneka Eurogentec
  527. Karolinska Institutet
  528. KBI Biopharma
  529. Kemwell Biopharma
  530. Kiadis Pharma
  531. Kineta
  532. Kite Pharma
  533. Kite Pharma (Acquired by Gilead Sciences)
  534. Kodiak Sciences
  535. KOLON Life Science
  536. KP Pharmaceutical Technology
  537. KPC Pharmaceuticals
  538. KUBio
  539. Kytopen
  540. Labyrinth BioPharma (Formely known as AB Biotechnology)
  541. LakePharma
  542. LamKap Bio
  543. LAMPIRE Biological Laboratories
  544. LaNova Medicines
  545. Lava Therapeutics
  546. Leanbio
  547. LEUKOCARE
  548. Levena Biopharma
  549. LFB
  550. Lipum
  551. List Biological Laboratories
  552. LNC Therapeutics
  553. Lokon Pharma
  554. Lonza
  555. LSNE Contract Manufacturing
  556. LucasPye BIO
  557. Luina Bio
  558. Lykan Bioscience
  559. Lyophilization Services of New England
  560. Lyophilization Technology
  561. Lysogene
  562. Mabion
  563. MabPlex
  564. MAbSilico
  565. Mab-Venture Biopharma
  566. MacroGenics
  567. Maine Biotechnology
  568. Malvern Panalytical
  569. Massachusetts Eye and Ear
  570. MassBiologics
  571. MaSTherCell
  572. Matica Biotechnology
  573. MaxiVAX
  574. Medeor Therapeutics
  575. Medigene
  576. MedImmune
  577. MEDINET
  578. Medisun Holdings
  579. Medix Biochemica
  580. MEMO Therapeutics
  581. Menarini Biotech
  582. Merck
  583. Merck Millipore
  584. Meridian Life Science
  585. Mesoblast
  586. Metastagen
  587. Meteoric Biopharmaceuticals
  588. MGB Biopharma
  589. MicroBiopharm Japan
  590. MicrofluidX
  591. Mila’s Miracle Foundation
  592. Milner Therapeutics Institute
  593. Minaris Regenerative Medicine
  594. Minneapolis Medical Research Foundation
  595. Mitsubishi Gas Chemical
  596. Moderna
  597. Molecular Medicine
  598. Molecular Partners
  599. Morphotek
  600. MSD
  601. MTI-GlobalStem
  602. Multispan
  603. Mundipharma
  604. Mycenax Biotech
  605. Mylab Discovery Solutions
  606. Najít Technologies
  607. Namocell
  608. Nan Fung
  609. Nanotein Technologies
  610. Naobios
  611. National Cancer Center Japan
  612. National Cancer Institute
  613. National Center for Advancing Translational Sciences
  614. National Health Research Institutes
  615. National Heart, Lung and Blood Institute
  616. National Institute of Allergy and Infectious Diseases
  617. National Institutes of Health
  618. Nature Technology
  619. Navrogen
  620. NBE-Therapeutics
  621. NeoProgen
  622. Neovacs
  623. NeoVentures Biotechnology
  624. Neuland
  625. NeuroFx
  626. NEUWAY Pharma
  627. Nikon
  628. Nikon CeLL innovation
  629. Nitto Avecia Pharma Services
  630. NIZO
  631. Nobelpharma
  632. Northway Biotech
  633. Northway BiotechPharma
  634. Nouscom
  635. NovalGen
  636. Novartis
  637. Novasep
  638. Novavax
  639. Novex Innovations
  640. NovoCodex Biopharmaceuticals
  641. Numab
  642. Numab Therapeutics
  643. NYU Langone Health
  644. OBI Pharma
  645. Ontario Bioscience Innovation Organization (OBIO
  646. Octane Biotech
  647. Ocugen
  648. Odylia
  649. Ology Bioservices
  650. Olon
  651. Omeros
  652. Omnia Biologics
  653. OmniChem
  654. Oncodesign
  655. OncoOne
  656. OncoQuest
  657. OncoVent
  658. Ondek
  659. Ono Pharmaceutical
  660. Oragenics
  661. Orchard Therapeutics
  662. Orgenesis
  663. ORPEGEN Peptide Chemicals
  664. Osaka University
  665. OSE Immunotherapeutics
  666. Osivax
  667. Otsuka Pharmaceutical
  668. Oxford BioMedica
  669. Oxford BioTherapeutics
  670. Oxford Genetics
  671. Oxford MEStar
  672. OXGENE
  673. Pace Life Sciences
  674. PacificGMP
  675. PackGene Biotech
  676. PaizaBio
  677. Pall
  678. Pall Corporation
  679. Panacea Biotec
  680. Panacea Pharmaceuticals
  681. PanCELLa
  682. Panolos Bioscience
  683. Paragon Bioservices
  684. Parker Institute for Cancer Immunotherapy
  685. Particle Sciences
  686. Passage Bio
  687. PATH
  688. Patheon
  689. PaxVax
  690. PCI Pharma Services
  691. PCT
  692. Peter MacCallum Cancer Centre
  693. Petrovax
  694. Pfizer
  695. Pfizer CentreOne
  696. Phanes Therapeutics
  697. PharmAbcine
  698. PharmaBio
  699. PharmaCell
  700. PharmaZell
  701. Pharmicell
  702. PhaseBio Pharmaceuticals
  703. pHion Therapeutics
  704. Pieris Pharmaceuticals
  705. Pierre Fabre
  706. Pinteon Therapeutics
  707. Pionyr Immunotherapeutics
  708. Piramal Pharma Solutions
  709. Plasma Industries Belgium (Formerly known as CAF-DCF)
  710. PlasmidFactory
  711. Polaris Pharmaceuticals
  712. Polpharma Biologics
  713. Polymun Scientific
  714. PolyPeptide Group
  715. Portola Pharmaceuticals
  716. Porton Biopharma
  717. Praxis Pharmaceutical
  718. Precirix
  719. Precision Antibody
  720. Precision NanoSystems
  721. Prevail Therapeutics
  722. PrimaPharma
  723. ProbioFerm
  724. ProBioGen
  725. Probiotical
  726. Probiotics Australia
  727. Profectus BioSciences
  728. Prokarium
  729. Prometic Life Sciences
  730. Propanc Biopharma
  731. Proteon Therapeutics
  732. Protexin
  733. Provia Labs
  734. PsiVac
  735. PTC Therapeutics
  736. PX'Therapeutics
  737. Q-Biologicals
  738. Quell Therapeutics
  739. Quratis
  740. Radimmune Therapeutics
  741. Rare Trait Hope Fund
  742. Recipharm
  743. Refana
  744. ReForm Biologics
  745. REGENXBIO
  746. Regulus Therapeutics
  747. Relief Therapeutics
  748. ReNeuroGen
  749. Rentschler Biopharma
  750. Rentschler Fill Solutions
  751. Resilience
  752. RevaTis
  753. Revolo Biotherapeutics
  754. RheinCell Therapeutics
  755. RiboBio
  756. Richter-Helm BioLogics
  757. Ridgeway Biologicals
  758. River Vision Development
  759. Roche
  760. Rocket Pharmaceuticals
  761. Roslin Cell Therapies
  762. RoslinCT
  763. Rznomics
  764. Saiba
  765. Sam Chun Dang Pharm
  766. Samsung Bioepis
  767. Samsung BioLogics
  768. SanBio
  769. Sandoz
  770. Sanofi
  771. Sanofi Pasteur
  772. Sanofi-Aventis
  773. Sanpower
  774. Santen Pharmaceutical
  775. Sarepta Therapeutics
  776. Sartorius Stedim Biotech
  777. Scancell
  778. SCD
  779. Scientific Protein Laboratories
  780. ScinoPharm
  781. Scorpion Biological Services
  782. Selecta Biosciences
  783. Serendex Pharmaceuticals
  784. Serum Institute of India
  785. Servier
  786. Shandong Luoxin Pharmaceutical
  787. Shanghai Jiao Tong University
  788. Shanghai Junshi Biosciences
  789. Sheba Medical Center
  790. Shenyang Sino-German Equipment Park
  791. Shenzhen Bao’an Sino-German (Europe) Industrial Development 
  792. Shenzhen Jianyi Biotechnology
  793. Shenzhen JYMed Technology
  794. Shilpa Biologicals
  795. Shire
  796. Showa Denko
  797. Siam Bioscience
  798. Siegfried
  799. SillaJen
  800. Singota Solutions
  801. SIRION Biotech
  802. Sistemic
  803. SK Bioscience
  804. Snapdragon Chemistry
  805. Sonnet BioTherapeutics
  806. Sorrento Therapeutics
  807. Spicona
  808. SpyBiotech
  809. ST Pharm
  810. Stanford University School of Medicine
  811. STCube
  812. Stelis Biosource
  813. Stellar Biotechnologies
  814. Stemmatters
  815. Sterling Pharma Solutions
  816. Stratophase
  817. Sumagen
  818. Sumitomo Dainippon Pharma
  819. Summa Life Sciences
  820. Sun Pharma
  821. Surface Oncology
  822. Surrozen
  823. Suzhou Kintor Pharmaceuticals
  824. Symbiosis Pharmaceutical Services
  825. Symphogen
  826. SynCo Bio Partners
  827. Synimmune
  828. Synklino
  829. Synpromics
  830. Synthace
  831. Synthelis
  832. Taisho Pharmaceutical
  833. Taiwan Liposome Company
  834. Takara Bio
  835. Takeda
  836. Taron Solutions
  837. TCR2 Therapeutics
  838. Tectron
  839. Telix Pharmaceuticals
  840. Tenboron
  841. TeneoBio
  842. Terumo
  843. Terumo BCT
  844. Teva Pharmaceuticals
  845. Tevogen Bio
  846. TG Therapeutics
  847. The Chemistry Research Solution
  848. The Michael J. Fox Foundation
  849. The Wistar Institute
  850. Themis Medicare
  851. TheraCell Advanced Biotechnology
  852. Therapure Biopharma
  853. Theravectys
  854. Thermo Fisher Scientific
  855. ThermoGenesis
  856. Thousand Oaks Biopharmaceuticals
  857. Tianjin Pharmaceutical
  858. TiGenix
  859. Tillotts Pharma
  860. Tizona Therapeutics
  861. T-knife
  862. Tmunity Therapeutics
  863. Tonix Pharmaceuticals
  864. TRACON Pharmaceuticals
  865. TrakCel
  866. Transgene
  867. Translate Bio
  868. Transporin
  869. TranXenoGen
  870. Treadwell Therapeutics
  871. Trefoil Therapeutics
  872. Trellis Bioscience
  873. Tri-Institutional Therapeutics Discovery Institute
  874. TRIANNI
  875. Trieza Therapeutics
  876. TriLink BioTechnologies
  877. TRIO Pharmaceuticals
  878. Triphase Accelerator
  879. Trizell
  880. Tsinghua University Innovation Center for Immune Therapy
  881. Tube Pharmaceuticals
  882. TxCell
  883. UAS Labs
  884. UGA Biopharma
  885. UK Cystic Fibrosis Gene Therapy Consortium
  886. Ultragenyx Pharmaceutical
  887. UNC Lineberger Comprehensive Cancer Center
  888. Unique Biotech
  889. University College London
  890. University of Aberdeen
  891. University of Birmingham
  892. University of California
  893. University of Leeds
  894. University of Manchester
  895. University of Pennsylvania
  896. University of Queensland
  897. University of Reading
  898. University of Sheffield
  899. University of South Australian
  900. University of Tokyo
  901. Uppsala BIO
  902. US Department of Defense
  903. US Government
  904. Vaccine and Infectious Disease Organization (VIDO)
  905. Vaccine Manufacturing and Innovation Centre
  906. Vaccitech
  907. ValenzaBio
  908. Valerius Biopharma
  909. Valneva
  910. Vanderbilt University Medical Center
  911. VascuLogic
  912. Vaxart
  913. VBI Vaccines
  914. VDDI Pharmaceuticals
  915. Vectron Biosolutions
  916. Verseau Therapeutics
  917. Vetter Pharma
  918. VGXI
  919. Vibalogics
  920. Vifor Pharma
  921. Vigene Biosciences
  922. Vineti
  923. Vir Biotechnology
  924. ViralGEN
  925. Virchow Biotech
  926. Virovek
  927. Viscofan
  928. VIVEbiotech
  929. Vivoryon Therapeutics (Formerly known as Probiodrug)
  930. Voyager Therapeutics
  931. Vaccine Research Institute (VRI)
  932. WACKER
  933. Waisman Biomanufacturing
  934. Walvax Biotechnology
  935. West Biotherapy
  936. WIL Research
  937. Winclove Probiotics
  938. WuXi AppTec
  939. WuXi Biologics
  940. Wuxi Griffin
  941. Xbrane Biopharma
  942. Xencor
  943. XL-protein
  944. Xpress Biologics
  945. Xyphos Biosciences
  946. Yapan Bio
  947. Yposkesi
  948. Yuhan
  949. Zealand Pharma
  950. Zelluna Immunotherapy
  951. Zhejiang Hisun Pharmaceutical
  952. Zhejiang Teruisi Pharmaceutical
  953. Zhittya Genesis Medicine
  954. Ziopharm Oncology
  955. Zumutor Biologics
  956. Zymeworks
  957. Zyngenia
  958. ZyVersa Therapeutics

Segmentation

Market Segments Details

Forecast Period

  • 2022 – 2035

Type of Service(s) Offered

  • API
  • FDF

Type of Biologic Manufactured

  • Antibodies
  • Cell Therapies
  • Vaccines
  • Other Biologics

Type of Expression System Used

  • Mammalian
  • Microbial
  • Others

Scale of Operation

  • Preclinical / Clinical
  • Commercial
Company Size
  • Small
  • Mid-sized
  • Large and Very Large

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • MENA
  • Latin America
  • Rest of the World 

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com